Patients’ and physicians’ satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic by Lisa Bishop et al.
Bishop et al. BMC Res Notes  (2015) 8:233 
DOI 10.1186/s13104-015-1187-8
RESEARCH ARTICLE
Patients’ and physicians’ satisfaction 
with a pharmacist managed anticoagulation 
program in a family medicine clinic
Lisa Bishop1*, Stephanie Young1, Laurie Twells1,2, Carla Dillon1 and John Hawboldt1
Abstract 
Background: A pharmacist managed anticoagulation service was initiated in a multi-physician family medicine 
clinic in December 2006. In order to determine the patient and physician satisfaction with the service, a study was 
designed to describe the patients’ satisfaction with the warfarin education and management they received from the 
pharmacist, and to describe the physicians’ satisfaction with the level of care provided by the pharmacist for patients 
taking warfarin. A self-administered survey was completed by both eligible patients receiving warfarin and physicians 
prescribing warfarin between December 2006 and May 2008. The patient survey collected information on patient 
demographics, satisfaction with warfarin education and daily warfarin management. The physician survey collected 
data about the satisfaction with patient education and daily anticoagulation management by the pharmacist.
Results: Seventy-six of 94 (81%) patients completed the survey. Fifty-nine percent were male with a mean age of 
65 years (range 24–90). Ninety-six percent agreed/strongly agreed the pharmacist did a good job teaching the impor-
tance of warfarin adherence, the necessity of INR testing and the risks of bleeding. Eighty-five percent agreed/strongly 
agreed the risk of blood clots was well explained, 79% felt the pharmacist did a good job teaching about dietary 
considerations and 77% agreed/strongly agreed the pharmacist explained when to see a doctor. All patients felt the 
pharmacist gave clear instructions on warfarin dosing and INR testing. Four of nine physicians (44%) completed the 
survey. All agreed/strongly agreed the pharmacist was competent in the care provided, were confident in the care 
their patients received, would like the pharmacist to continue the service, and would recommend this program to 
other clinics.
Conclusions: Patients and family physicians were satisfied with the pharmacist managed anticoagulation program 
and recommended continuation of the program. These results support the role of the pharmacist in the management 
of anticoagulation in a multi-physician family medicine clinic.
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Background
Warfarin therapy is well established and has been the 
main oral anticoagulant used for the prevention and 
treatment of thromboembolism. Patients taking war-
farin require close blood monitoring to maintain their 
international normalized ratio (INR) within therapeutic 
range to ensure effectiveness and to minimize the risk of 
bleeding. This is challenging in clinical practice due to 
inter-patient variability and the susceptibility of warfarin 
to pharmacokinetic changes due to concurrent medica-
tions, diet, and various disease states [1]. The Institute for 
Safe Medication Practices (ISMP) maintains a list of high 
alert medications, which includes warfarin [2]. ISMP 
noted that when used or omitted in error, anticoagulants, 
such as warfarin, can cause life threatening bleeding or 
thrombosis.
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The American College of Chest Physicians (ACCP) 
guidelines recommends that “health-care providers 
who manage oral anticoagulation therapy should do so 
in a systematic and coordinated fashion, incorporating 
patient education, systematic INR testing, tracking, fol-
low-up, and good patient communication of results and 
dosing decisions” [1]. Evidence indicates that a coordi-
nated pharmacist managed anticoagulation program is 
associated with less adverse events and hospitalization 
admissions as compared to usual care [3, 4]. A recent 
meta-analysis indictated that pharmacist-participated 
warfarin management therapy significantly reduced 
total bleeding, with a non-significant trend towards 
decreases in other warfarin-related complications [5]. 
Despite this evidence, many anticoagulated patients do 
not receive care from such services. Optimum delivery 
of anticoagulation therapy should be a priority of all cli-
nicians involved in the care of patients receiving antico-
agulation therapy. Required components for optimized 
delivery and evaluation of these specialized services 
exist [6].
Several target specific oral anticoagulants (TSOAC) 
are available in Canada which have more predictable 
pharmacologic and pharmacokinetic properties than 
warfarin, thus eliminating the need for frequent INR 
monitoring [7–9]. Due to the ease of administration and 
reduced monitoring of these agents, they may replace 
the use of warfarin for many indications [10, 11]. Known 
contraindications, emerging reports of serious adverse 
events, and lack of anticoagulation reversibility results in 
situations where warfarin remains the drug of choice [10, 
12]. The principles of patient selection, provider educa-
tion and training, interruption of treatment for invasive 
procedures, and careful follow-up will remain, resulting 
in a reliance on specialized anticoagulation programs to 
effectively manage anticoagulation.
Generally, patient and physician satisfaction with anti-
coagulation programs is reported as high [13–17]. Wil-
ley et  al. [13] evaluated satisfaction surveys mailed to 
patients and referring physicians of a pharmacist-man-
aged outpatient anticoagulation clinic. Overall, both 
patients and physicians were very satisfied with the 
clinic and physicians indicated the care provided by the 
clinic decreased their workload. Significant differences 
favoring the presence of anticoagulation clinics have 
also been noted in several studies [14, 15, 17]. In these 
studies, patient satisfaction was measured in anticoagu-
lation clinics and then compared to physician-managed 
care. Finally, one study found in the literature examined 
pharmacist anticoagulation management integrated into 
a private physician office setting [16]. All patients agreed 
or strongly agreed that they were satisfied with the over-
all service provided to them by the pharmacist. There is 
limited information on patient and physician satisfaction 
with anticoagulation programs in private physician office 
settings.
In Newfoundland and Labrador (NL), Canada, outpa-
tients on warfarin are generally managed by their fam-
ily physician. In 2006, a pharmacist-run anticoagulation 
service was initiated at a family medicine clinic in NL. 
The pharmacist obtained the INR result from the local 
laboratory, contacted patients primarily via telephone, 
and used an electronic medical record to document the 
encounters and communicate with the physicians. An 
evaluation of the anticoagulation service demonstrated 
that the pharmacist provided service achieved sig-
nificantly better INR control as compared to usual care 
[18]. The specific objectives of the present study were to 
describe patients’ satisfaction with the warfarin educa-
tion and management they received from the pharmacist, 
and to describe the physicians’ satisfaction with the level 
of care provided by the pharmacist for their patients tak-
ing warfarin. Information from this research will be used 
to support the role of the pharmacist in the management 
of anticoagulation in a family medicine clinic.
Methods
Selection of study participants
The study was conducted in August 2008, with sampling 
of all patients who received anticoagulation management 
by the pharmacist at the family practice clinic and all 
physicians who prescribed warfarin between December 
7, 2006 and May 7, 2008. All patients enrolled in the pro-
gram and who had at least one INR blood test that was 
managed by the pharmacist between this time period 
were included in the study. Patients were excluded if 
they were deceased or if a current address could not be 
located.
Setting
The family practice clinic is located in St. John’s, NL, a 
capital city with a population of approximately 200,600 
[19]. In December 2006, the primary healthcare phar-
macist at the family practice clinic initiated an antico-
agulation program, which was the first of its kind in NL. 
The program was primarily a telephone-based service 
to educate, counsel, and instruct patients on the use of 
warfarin, which was overseen by the family physicians. 
Written patient educational material was provided to all 
the patients which summarized the education provided 
by the pharmacist regarding their warfarin therapy. This 
material was developed by the pharmacists. A physician-
approved protocol was used by the pharmacist for the 
education and day-to-day management of patients taking 
warfarin. Additional details about the service have been 
described previously [18].
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Survey method
All eligible patients and physicians were mailed an anon-
ymous survey printed on bright, colored paper, with an 
accompanying cover letter and self-addressed, return 
stamped envelope. A follow-up reminder letter and sur-
vey was mailed 2 weeks after the first survey to all eligible 
participants. Completion of the survey was considered 
consent to participate.
Survey design
Literature searches of PubMed, EMBASE, IPA and Pro-
Quest Dissertations and Theses were conducted to iden-
tify existing patient and physician surveys on satisfaction 
with anticoagulation programs. If needed, study authors 
were contacted. Existing surveys were taken into consid-
eration when developing the surveys used in the present 
study, along with articles on how to design questionnaires 
[13, 14, 16, 20–26]. The surveys were designed with input 
from all research team members.
The patient survey consisted of 14 statements which 
gathered information about the warfarin education pro-
vided by the pharmacist, as well as opinions around the 
daily management of warfarin, including instructions 
regarding the dose of warfarin, when to get an INR test, 
if calls from the pharmacist were returned, if the pharma-
cist could answer questions, if the pharmacist was cour-
teous and respectful, if the patients were aware of the 
pharmacists collaboration with other health profession-
als, and overall service satisfaction. Demographic infor-
mation collected included sex, year of birth, highest level 
of education, duration of warfarin use, and how the par-
ticipant’s warfarin was managed prior to the pharmacist.
The physician survey consisted of eleven statements, 
which gathered information concerning level of satis-
faction with patient education provided by the pharma-
cist as well as the daily management of their warfarin 
patients. Questions included whether they felt the phar-
macist was competent, if they now felt more comfortable 
managing patients on warfarin, if they were contacted 
if issues arose, if they were kept up-to-date on therapy 
changes, if their time on warfarin issues had decreased, 
if adverse events had decreased, and their overall opinion 
of the service.
Opinions for both surveys were captured via a 5-point 
Likert scales ranging from strongly agree to strongly 
disagree. For these questions, responses were collapsed 
to three categories of “agree” (included strongly agree 
and agree), “uncertain”, and “disagree” (included strongly 
disagree and disagree), and reported as percentage of 
agreement or disagreement for each statement. Open 
responses were also captured.
The questions as they appeared on the surveys are 
included in the results tables (Tables 1, 2, 3).
Statistical analysis
A sample size calculation was not required given that all 
eligible the patients and physicians were surveyed. Data 
was entered into SPSS statistical software for Windows 
(version 16.0) spreadsheet for analysis. Descriptive statis-
tics were used for all questions.
Ethics approval
The Human Investigations Committee at Memorial Uni-
versity approved the research protocol.
Results
Patient survey
Of the 112 patients managed by the pharmacist, 94 met 
the eligibility criteria after exclusion of 18 patients (six 
were deceased and 12 could not be located). All eligi-
ble patients were mailed surveys and 76 were returned, 
providing a response rate of 81%. The demographics 
of the patients are reported in Table  4. The majority of 
patients were male with a mean age of 65. At the time 
of the survey, most patients (47%) reported taking war-
farin for 1–5  years, 28% reported more than 5  years of 
use and 24% less than 1  year of therapy. The majority 
(81%) of patients reported being managed by their family 
Table 1 Patient satisfaction with warfarin education from pharmacist (n = 76)
Statement n (%)
Agree or strongly agree Uncertain Disagree or strongly degree Missing
The clinic pharmacist did a good job teaching me about:
 Why I should take my warfarin everyday 69 (96) 3 (4) 0 4
 Why I need to have my INR blood test done 72 (97) 2 (3) 0 2
 The risks of bleeding which may occur with warfarin 70 (95) 3 (4) 1 (1) 2
 The risk of a blood clot if my INR blood test is too low 62 (85) 9 (12) 2 (3) 3
 When I need to see a doctor or go to the emergency room 56 (77) 14 (19) 3 (4) 3
 What foods may affect warfarin 57 (79) 12 (17) 3 (4) 4
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physician prior to the pharmacist-managed program, 
while 12% were only managed by the pharmacist, and 7% 
indicated “not sure or not applicable”.
Almost all patients were satisfied with the warfarin 
education provided by the pharmacist. At least 95% of 
patients agreed/strongly agreed that the pharmacist com-
pleted a satisfactory job teaching the importance of war-
farin adherence, why INR tests were necessary, and the 
risks of bleeding. Approximately 75% agreed/strongly 
agreed that the risk of a blood clot was explained, 
that dietary considerations for warfarin therapy were 
described, and that they were told when to see a doctor. 
Table  1 outlines the breakdown of responses regarding 
patient satisfaction with the warfarin education.
All patients reported being satisfied with the serviced 
provided by the pharmacist and reported as “trusting” the 
pharmacist (Table  2). All patients also agreed/strongly 
agreed that the pharmacist gave clear instructions on the 
Table 2 Patient satisfaction with warfarin management from pharmacist (n = 76)
Statement n (%)
Agree or strongly agree Uncertain Disagree or strongly disagree? Missing
The clinic pharmacist gave me clear instructions about what dose 
of warfarin to take
75 (100) 0 0 1
The clinic pharmacist gave me clear instructions about when to  
get my INR blood test done
75 (100) 0 0 1
The clinic pharmacist returned my calls in a timely fashion 73 (99) 1 (1) 0 2
The clinic pharmacist treated me with courtesy and respect 75 (100) 0 0 1
I trust the clinic pharmacist to answer my questions about  
warfarin
75 (100) 0 0 1
I am satisfied with the service provided by the clinic pharmacist  
in managing my warfarin
75 (100) 0 0 1
The clinic pharmacist worked with other health care professionals 
to help manage my warfarin
53 (77) 15 (22) 1 (1) 7
Other patients taking warfarin would benefit from this type of 
service
74 (100) 0 0 2
Table 3 Physician satisfaction survey results (n = 4)
Statement n (%)
Agree or strongly  
agree
Neutral Disagree or strongly 
disagree
The clinic pharmacist is competent in the management of warfarin 4 (100) 0 0
I am more confident in initiating or managing new patients on warfarin when the 
clinic pharmacist is involved
4 (100) 0 0
I am contacted appropriately by the clinic pharmacist when issues arise with  
warfarin management for my patients
4 (100) 0 0
I am kept up-to-date on changes in warfarin therapy for my patients in a timely  
manner
4 (100) 0 0
Warfarin management by the clinic pharmacist has decreased the number  
of questions I receive from patients about warfarin
3 (75) 1 (25) 0
Warfarin management by the clinic pharmacist has decreased the amount  
of time I spend on anticoagulation issues for my patients
3 (75) 1 (25) 0
My patients have a better understanding of warfarin therapy since they have been 
managed by the clinic pharmacist
4 (100) 0 0
The clinic pharmacist managed warfarin program has improved continuity of care  
for my patients
4 (100) 0 0
Close monitoring of warfarin by the clinic pharmacist has decreased the likelihood  
of adverse events in my patients
4 (100) 0 0
I would like to continue having the clinic pharmacist manage warfarin in my patients 4 (100) 0 0
I would recommend to my colleagues in other clinics to initiate a pharmacist- 
managed warfarin services
4 (100) 0 0
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dose of warfarin and when to get their INR test repeated. 
Over 75% agreed/strongly agreed that the pharmacist 
worked with other health care providers in the manage-
ment of their warfarin.
Forty-six patients provided additional written com-
ments, which were all positive. Examples of comments 
included: “…the pharmacist warfarin program is a great 
addition and hope it will continue”; “It is a useful service. 
Much better than just dealing with your physician for 
INR testing and results”; “I was getting comprehensive 
care”; “More doctors’ offices should be using it!”; “…made 
everything easy and consistent”; “It’s reliable, dependable 
and more thorough.”
Physician survey
Of the nine physicians who were mailed a survey, four 
(44%) completed the survey. All the physicians indicated 
they were happy with the pharmacist-managed program 
and agreed/strongly agreed that other clinics should ini-
tiate a similar program. Three-quarters of the physicians 
agreed/strongly agreed that the program decreased the 
number of questions from patients about warfarin and 
decreased the amount of time they spent on anticoagu-
lation issues. Details of the physician satisfaction results 
are listed in Table 3.
Additional written comments were provided by the 
physicians who responded to the survey. The comments 
were all positive, including such things as “great ser-
vice”; “…more in depth care and communication with the 
patient”; “Patients love the ability they have to contact 
pharmacist re: the warfarin and any questions they have 
regarding their medications…”; “… always stay within 
their scope and refer to doctors appropriately and keep 
us informed”.
Discussion
The results of this study indicate that the patients 
who received care from the pharmacist-managed 
anticoagulation program were satisfied with the 
service provided and felt that this program should 
be expanded to other family medicine clinics. Most 
patients were also satisfied with the education they 
received, which included information about why they 
needed to take warfarin, the risks of bleeding, and 
potential thromboembolism. The physicians were also 
satisfied with the program, with all physicians feeling 
confident in the care provided to the patients and indi-
cating that other family physician offices could benefit 
from such a service.
The overall satisfaction of our program from patients 
who received care was 100%, which is similar to other 
studies. Overall patient satisfaction with anticoagula-
tion services has been cited in the literature as ranging 
from 95 to 100% [13–17]. Garwood et  al. [14] consid-
ered whether transitioning patients from a pharmacist-
managed anticoagulation clinic to a physician-managed 
care alters the quality of care. Statistically significant 
differences favoring pharmacist-managed anticoagula-
tion were noted in all areas of clinical care. These results 
suggested that the patients believed the pharmacist had 
more expertise in managing anticoagulation control 
when compared with their physician. Although our study 
did not look at the transition from pharmacist manage-
ment back to physician management, all patients indi-
cated that they trusted the pharmacist to answer their 
questions, and over three quarters were satisfied with the 
anticoagulation education they received.
Additional studies have demonstrated patient and 
physician confidence in pharmacist managed anticoagu-
lation. In a community-pharmacy led anticoagulation 
service, attitudes towards a pharmacist model of man-
agement showed that most patients (79%) and physicians 
(89%) were confident in the pharmacist’s ability to man-
age therapy [26]. In an outpatient pharmacist-managed 
anticoagulation clinic that was associated with a local 
hospital, both patient and physicians demonstrated a 
high level of satisfaction with the service [27].
The setting of our study was a private family physician 
office, which was similar to a study by Ernst et  al. [16]. 
In this study they examined the anticoagulation man-
agement that occurred in a private physician office set-
ting. Results indicated that all patients agreed that they 
were satisfied with the overall service provided to them 
by the pharmacist, felt the pharmacist was courteous, felt 
they increased their knowledge of warfarin, and would 
recommend this service to other patients. The physi-
cians also reported satisfaction with the pharmacist-
run service, demonstrating that the clinic is convenient, 
provides better continuity of care, results in fewer ques-
tions, and would prefer to have patients handled through 
the anticoagulation clinic. These findings are consist-
ent with our study, which emphasized the benefit of 
Table 4 Patient baseline characteristics (n = 76)
* Not all respondents replied to each question.
Respondent characteristics Result n* %
Sex
 Male 42 59
 Female 29 41
Age years, mean (SD) 65 (16)
 Min, max in years 24–90
Highest level education
 Post-secondary 47 66
 High School 15 21
 Grade School 9 13
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pharmacist-managed anticoagulation programs in a pri-
vate family office setting.
An evaluation of our pharmacist-managed anticoagu-
lation service demonstrated a significantly better INR 
control for the pharmacist-managed care as compared 
to usual care by the physicians, with the time in thera-
peutic range 73 vs. 65%, respectively (p  <  0.0001) [18]. 
This current study adds to the evidence supporting the 
benefit of the service by showing that patients and phy-
sicians are satisfied with a telephone based program in 
a private family physician office. Since pharmacists who 
work directly in a family practice setting is limited in NL, 
the results of this study support exploring the extension 
of this model to other family medicine practice sites. The 
impact of the TSOAC on the current anticoagulation 
programs in family medicine would be an interesting area 
of future research.
There are several strengths to our study. The response 
rate from both the patients (81%) and physicians (44%) 
was comparable or better than other similar studies [13–
17, 26, 27]. We also increased our response rate to the 
survey by mailing out a second survey to all potential par-
ticipants 2 weeks after the original survey as a reminder 
to complete the survey. The survey was anonymous and 
did not collect any identifying data so the patients and 
physicians should have felt comfortable responding to 
the survey.
There were some limitations to our study. This was a 
retrospective cross-sectional survey so some patients 
may have had difficulty remembering their encounters 
with the pharmacist if they used the service for only a 
short time period or had not used the service recently. In 
addition, many of the patients were on warfarin before 
the anticoagulation service was established while others 
initiated warfarin using the pharmacist-run service. This 
may have influenced the responses of the patients, in par-
ticular the questions about the education they received 
from the pharmacist. Our study did not have a compari-
son with usual physician managed care. Since the phar-
macist took over the management of warfarin in 2006, we 
felt that there would be inaccuracies in patients recalling 
their experiences prior to this time. As well, we did not 
capture the patient’s perceptions of their INR and warfa-
rin control since being managed by the pharmacist. We 
did not feel that this was necessary as the patient’s INR 
control was systematically collected over the same time 
period and was shown to be better than usual care [18]. 
Although the survey tool was designed based on previ-
ously published survey tools used in the literature, the 
survey tools were not validated for evaluating an antico-
agulation service. Some factors that may limit the gener-
alizability of the results, as it was conducted at a single 
site and there were only four physician responses to the 
survey. This study was also based on a service from 2006 
to 2008; however, this data is still applicable as warfarin 
remains a commonly used anticoagulant in practice.
Conclusions
Patients and family physicians were satisfied with the 
pharmacist-managed anticoagulation program in a multi-
physician family medicine clinic and recommended con-
tinuation of the program. The service is highly valued by 
both patients and family physicians and can support the 
role of the pharmacist in the management of anticoagula-
tion in a multi-physician family medicine clinic.
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